⚖
Compare Funds
See how two funds stack up side by side, real returns, risk, cost and portfolio overlap.
VS
Key Metrics Comparison
| Metric | Nippon India Nifty Pharma ETF | Motilal Oswal NASDAQ Q 50 ETF |
|---|---|---|
| Snapshot | ||
| AMC | — | — |
| Category | ETFs - Index | ETFs - Other |
| NAV | ₹27.89 (30 Oct 2026) | ₹117.63 (30 Oct 2026) |
| Rating | ★★★★★ | ★★★★★ |
| Benchmark | NIFTY PHARMA - TRI | NASDAQ Q-50-TRI |
| Fund Manager | Jitendra Tolani | Swapnil P Mayekar |
| Inception | 06 Jul 2021 | 23 Dec 2021 |
| Returns | ||
| 1Y | 19.51% | 39.69% |
| 3Y | 22.35% | 35.85% |
| 5Y | 14.55% | — |
| Since Inception | 12.89% | 13.62% |
| Risk | ||
| 13.99 | 18.57 | |
| 1.00 | 0.40 | |
| 1.00 | 1.31 | |
| -0.19 | 24.06 | |
| 2.18 | 2.77 | |
| -9.63% | -16.13% | |
| Costs | ||
| Expense Ratio | 0.23% | 0.56% |
| Exit Load | — | — |
| Min SIP | — | — |
| Min Lumpsum | ₹1,000 | ₹500 |
| Lock-in | None | None |
Min SIP is reported per fund, not per plan, every plan of a fund shares the same figure.
Portfolio Overlap
Nippon India …100%
Motilal Oswal…100%
0.0%Only 0.0% of holdings by weight are common between Nippon India Nifty Pharma ETF and Motilal Oswal NASDAQ Q 50 ETF, based on each fund's top 20 disclosed holdings, not the full portfolio.
Category context: Index / ETF vs Index / ETF. Open the full Screener →